OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research report on Wednesday, November 13th.

OncoCyte Trading Down 4.2 %

Shares of OncoCyte stock opened at $2.53 on Tuesday. The stock has a fifty day simple moving average of $2.96 and a 200 day simple moving average of $2.98. OncoCyte has a 12-month low of $2.29 and a 12-month high of $4.30.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same quarter in the previous year, the business posted ($0.57) EPS.

Insider Transactions at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 26.69 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Andrea S. James purchased 33,670 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was bought at an average cost of $2.97 per share, with a total value of $99,999.90. Following the purchase, the chief financial officer now owns 33,670 shares in the company, valued at approximately $99,999.90. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.58% of the company’s stock.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC boosted its stake in OncoCyte Co. (NASDAQ:OCX) by 12.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the period. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 at the end of the most recent reporting period. 55.35% of the stock is owned by hedge funds and other institutional investors.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.